Application of mathematical models to metronomic chemotherapy: What can be inferred from minimal parameterized models?

[1]  R. Kerbel,et al.  Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect , 2016, Nature Reviews Clinical Oncology.

[2]  Shuo Wang,et al.  Optimal control of a mathematical model for cancer chemotherapy under tumor heterogeneity. , 2016, Mathematical biosciences and engineering : MBE.

[3]  U. Ledzewicz,et al.  On drug resistance and metronomic chemotherapy: A mathematical modeling and optimal control approach. , 2016, Mathematical biosciences and engineering : MBE.

[4]  Nicolas André,et al.  Computational oncology — mathematical modelling of drug regimens for precision medicine , 2016, Nature Reviews Clinical Oncology.

[5]  H. Schättler,et al.  Dynamical properties of a minimally parameterized mathematical model for metronomic chemotherapy , 2016, Journal of mathematical biology.

[6]  J. Coldman.  Drug resistance in cancer , 2016 .

[7]  Katarzyna A Rejniak,et al.  Limiting the Development of Anti-Cancer Drug Resistance in a Spatial Model of Micrometastases , 2016, bioRxiv.

[8]  Nicolas André,et al.  Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine. , 2015, Seminars in cancer biology.

[9]  Philipp M. Altrock,et al.  The mathematics of cancer: integrating quantitative models , 2015, Nature Reviews Cancer.

[10]  Urszula Ledzewicz,et al.  Optimal Control for Mathematical Models of Cancer Therapies: An Application of Geometric Methods , 2015 .

[11]  H. Schättler,et al.  Dynamics and control of a mathematical model for metronomic chemotherapy. , 2015, Mathematical biosciences and engineering : MBE.

[12]  Alexander Lorz,et al.  Emergence of drug tolerance in cancer cell populations: an evolutionary outcome of selection, nongenetic instability, and stress-induced adaptation. , 2015, Cancer research.

[13]  Urszula Ledzewicz,et al.  A 3-Compartment Model for Chemotherapy of Heterogeneous Tumor Populations , 2015 .

[14]  N. McGranahan,et al.  Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. , 2015, Cancer cell.

[15]  William Pao,et al.  The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells , 2015, Cancer informatics.

[16]  B. Perthame,et al.  Modeling the Effects of Space Structure and Combination Therapies on Phenotypic Heterogeneity and Drug Resistance in Solid Tumors , 2014, Bulletin of Mathematical Biology.

[17]  K. Nan,et al.  New insights into metronomic chemotherapy-induced immunoregulation. , 2014, Cancer letters.

[18]  M. Chaplain,et al.  Mathematical modeling of tumor growth and treatment. , 2014, Current pharmaceutical design.

[19]  F. Michor,et al.  Evolution of acquired resistance to anti-cancer therapy. , 2014, Journal of theoretical biology.

[20]  N. André,et al.  Metronomics: towards personalized chemotherapy? , 2014, Nature Reviews Clinical Oncology.

[21]  Martin A. Nowak,et al.  Spatial Heterogeneity in Drug Concentrations Can Facilitate the Emergence of Resistance to Cancer Therapy , 2014, PLoS Comput. Biol..

[22]  Urszula Ledzewicz,et al.  ON OPTIMAL CHEMOTHERAPY FOR HETEROGENEOUS TUMORS , 2014 .

[23]  N. André,et al.  Metronomics as Maintenance Treatment in Oncology: Time for Chemo-Switch , 2014, Front. Oncol..

[24]  Quanxu Ge,et al.  CURVATURE-BASED CORRECTION ALGORITHM FOR AUTOMATIC LUNG SEGMENTATION ON CHEST CT IMAGES , 2014 .

[25]  Charles Swanton,et al.  Cancer evolution: the final frontier of precision medicine? , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  M. Gottesman,et al.  The Impact of Cell Density and Mutations in a Model of Multidrug Resistance in Solid Tumors , 2014, Bulletin of Mathematical Biology.

[27]  Florence Hubert,et al.  MATHEMATICAL MODEL OF CANCER GROWTH CONTROLED BY METRONOMIC CHEMOTHERAPIES , 2013 .

[28]  Philip Hahnfeldt,et al.  Maximum tolerated dose versus metronomic scheduling in the treatment of metastatic cancers. , 2013, Journal of theoretical biology.

[29]  P. Hahnfeldt,et al.  Center of cancer systems biology second annual workshop--tumor metronomics: timing and dose level dynamics. , 2013, Cancer research.

[30]  Urszula Ledzewicz,et al.  On the MTD paradigm and optimal control for multi-drug cancer chemotherapy. , 2013, Mathematical biosciences and engineering : MBE.

[31]  Urszula Ledzewicz,et al.  OPTIMAL CONTROLS FOR A MATHEMATICAL MODEL OF TUMOR-IMMUNE INTERACTIONS UNDER TARGETED CHEMOTHERAPY WITH IMMUNE BOOST , 2013 .

[32]  Alberto Gandolfi,et al.  The Norton–Simon hypothesis and the onset of non-genetic resistance to chemotherapy induced by stochastic fluctuations , 2012 .

[33]  M. Chaplain,et al.  Evasion of tumours from the control of the immune system: consequences of brief encounters , 2012, Biology Direct.

[34]  B. Perthame,et al.  Populational adaptive evolution, chemotherapeutic resistance and multiple anti-cancer therapies , 2012, 1207.0923.

[35]  N. André,et al.  Pilot study of a pediatric metronomic 4-drug regimen , 2011, Oncotarget.

[36]  Avner Friedman,et al.  Tumor cells proliferation and migration under the influence of their microenvironment. , 2011, Mathematical biosciences and engineering : MBE.

[37]  Nicolas André,et al.  Metronomic scheduling of anticancer treatment: the next generation of multitarget therapy? , 2011, Future oncology.

[38]  Durjoy Majumder,et al.  TUMOR ANGIOGENESIS BASED ANALYTICAL MODEL FOR THE ASSESSMENT OF MCT AND MTD CHEMOTHERAPEUTIC STRATEGIES IN CANCER , 2010 .

[39]  Nicolas André,et al.  Metronomic chemotherapy: new rationale for new directions , 2010, Nature Reviews Clinical Oncology.

[40]  Alberto Gandolfi,et al.  Chemotherapy of vascularised tumours: role of vessel density and the effect of vascular "pruning". , 2010, Journal of theoretical biology.

[41]  Joaquim Bellmunt,et al.  Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). , 2010, The Lancet. Oncology.

[42]  Alberto d'Onofrio,et al.  Bounded-noise-induced transitions in a tumor-immune system interplay. , 2010, Physical review. E, Statistical, nonlinear, and soft matter physics.

[43]  Franziska Michor,et al.  Evolution of Resistance to Targeted Anti-Cancer Therapies during Continuous and Pulsed Administration Strategies , 2009, PLoS Comput. Biol..

[44]  A. Gandolfi,et al.  The dynamics of tumour–vasculature interaction suggests low‐dose, time‐dense anti‐angiogenic schedulings , 2009, Cell proliferation.

[45]  R. Gatenby.  A change of strategy in the war on cancer , 2009, Nature.

[46]  Urszula Ledzewicz,et al.  On the Optimality of Singular Controls for a Class of Mathematical Models for Tumor Anti-Angiogenesis , 2009 .

[47]  H. Schättler,et al.  Optimal and suboptimal protocols for a class of mathematical models of tumor anti-angiogenesis. , 2008, Journal of theoretical biology.

[48]  A. Friedman.  MATHEMATICAL ANALYSIS AND CHALLENGES ARISING FROM MODELS OF TUMOR GROWTH , 2007 .

[49]  Urszula Ledzewicz,et al.  AntiAngiogenic Therapy in Cancer Treatment as an Optimal Control Problem , 2007, SIAM J. Control. Optim..

[50]  Alberto Gandolfi,et al.  The response to antiangiogenic anticancer drugs that inhibit endothelial cell proliferation , 2006, Appl. Math. Comput..

[51]  L. Norton,et al.  The Norton–Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens , 2006, Nature Clinical Practice Oncology.

[52]  I. Tannock,et al.  The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. , 2006, Cancer research.

[53]  Urszula Ledzewicz,et al.  Drug resistance in cancer chemotherapy as an optimal control problem , 2005 .

[54]  E. Afenya.  Using mathematical modeling as a resource in clinical trials. , 2005, Mathematical biosciences and engineering : MBE.

[55]  Kristian Pietras,et al.  A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  Alberto Gandolfi,et al.  Tumour eradication by antiangiogenic therapy: analysis and extensions of the model by Hahnfeldt et al. (1999). , 2004, Mathematical biosciences.

[57]  Robert S. Kerbel,et al.  The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.

[58]  Ricard V. Solé,et al.  Phase transitions in unstable cancer cell populations , 2003 .

[59]  L. Wein,et al.  Optimal scheduling of radiotherapy and angiogenic inhibitors , 2003, Bulletin of mathematical biology.

[60]  P. Hahnfeldt,et al.  Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. , 2003, Journal of theoretical biology.

[61]  R. Kerbel,et al.  Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. , 2002, Cancer research.

[62]  Urszula Ledzewicz,et al.  Optimal Bang-Bang Controls for a Two-Compartment Model in Cancer Chemotherapy , 2002 .

[63]  Rakesh K. Jain,et al.  Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.

[64]  E Glatstein,et al.  High-time chemotherapy or high time for low dose. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  Gabriele Bergers,et al.  Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. , 2000, The Journal of clinical investigation.

[66]  Peter Bohlen,et al.  Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity , 2000 .

[67]  J. Folkman,et al.  Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. , 2000, Cancer research.

[68]  H M Byrne,et al.  A mathematical model to study the effects of drug resistance and vasculature on the response of solid tumors to chemotherapy. , 2000, Mathematical biosciences.

[69]  P. Hahnfeldt,et al.  Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. , 1999, Cancer research.

[70]  P. Hahnfeldt,et al.  Cell resensitization during protracted dosing of heterogeneous cell populations. , 1998, Radiation research.

[71]  Jaroslaw Smieja,et al.  Cell Cycle as an Object of Control , 1995 .

[72]  A. Perelson,et al.  Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. , 1994, Bulletin of mathematical biology.

[73]  E. Glatstein,et al.  Back to the basics: the importance of concentration x time in oncology. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  Zvia Agur,et al.  Reduction of cytotoxicity to normal tissues by new regimens of cell-cycle phase-specific drugs , 1988 .

[75]  A. Zhabotinsky,et al.  Mathematical model of cancer chemotherapy. periodic schedules of phase-specific cytotoxic-agent administration increasing the selectivty of therapy , 1985 .

[76]  J. Goldie,et al.  A model for the resistance of tumor cells to cancer chemotherapeutic agents , 1983 .

[77]  Martin M. Eisen,et al.  Mathematical Models in Cell Biology and Cancer Chemotherapy , 1979 .

[78]  L. Norton,et al.  Tumor size, sensitivity to therapy, and design of treatment schedules. , 1977, Cancer treatment reports.

[79]  H. Skipper,et al.  The effects of chemotherapy on the kinetics of leukemic cell behavior. , 1965, Cancer research.

[80]  H. Skipper,et al.  EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIII. ON THE CRITERIA AND KINETICS ASSOCIATED WITH "CURABILITY" OF EXPERIMENTAL LEUKEMIA. , 1964, Cancer chemotherapy reports.

[81]  Katarzyna A. Rejniak,et al.  Systems Biology of Tumor Microenvironment , 2016, Advances in Experimental Medicine and Biology.

[82]  Urszula Ledzewicz,et al.  Optimizing Chemotherapeutic Anti-cancer Treatment and the Tumor Microenvironment: An Analysis of Mathematical Models. , 2016, Advances in experimental medicine and biology.

[83]  P. Hahnfeldt,et al.  The Power of the Tumor Microenvironment: A Systemic Approach for a Systemic Disease , 2014 .

[84]  H. Schättler,et al.  A Review of Optimal Chemotherapy Protocols: From MTD towards Metronomic Therapy , 2014 .

[85]  H. Schättler,et al.  Tumor Microenvironment and Anticancer Therapies: An Optimal Control Approach , 2014 .

[86]  M. Gottesman,et al.  Integrated Systems and Technologies : Mathematical Oncology The Role of Cell Density and Intratumoral Heterogeneity in Multidrug Resistance , 2013 .

[87]  P. Hahnfeldt,et al.  Integrated Systems and Technologies : Mathematical Oncology Tumor – Immune Dynamics Regulated in the Microenvironment Inform the Transient Nature of Immune-Induced Tumor Dormancy , 2013 .

[88]  Christian Faivre,et al.  Modeling the Impact of Anticancer Agents on Metastatic Spreading , 2012 .

[89]  Jean Clairambault,et al.  Modelling Physiological and Pharmacological Control on Cell Proliferation to Optimise Cancer Treatments , 2009 .

[90]  A. Świerniak,et al.  Direct and indirect control of cancer populations , 2008 .

[91]  Nicola Bellomo,et al.  Comprar Selected Topics in Cancer Modeling · Genesis, Evolution, Immune Competition, and Therapy | Bellomo, Nicola | 9780817647124 | Springer , 2008 .

[92]  Abhik Mukherjee,et al.  Mathematical modelling for the assessment of the effect of drug application delays in metronomic chemotherapy of cancer due to physiological constraints , 2008, Biosyst..

[93]  A. Friedman.  Cancer Models and Their Mathematical Analysis , 2006 .

[94]  J. Goldie.  Drug Resistance in Cancer: A Perspective , 2004, Cancer and Metastasis Reviews.

[95]  Zvia Agur,et al.  Drug resistance as a dynamic process in a model for multistep gene amplification under various levels of selection stringency , 2004, Cancer Chemotherapy and Pharmacology.

[96]  G. W. Swan,et al.  General applications of optimal control theory in cancer chemotherapy. , 1988, IMA journal of mathematics applied in medicine and biology.

[97]  T. Wheldon.  Mathematical models in cancer research , 1988 .

[98]  H. Skipper.  On mathematical modeling of critical variables in cancer treatment (goals: Better understanding of the past and better planning in the future) , 1986, Bulletin of mathematical biology.

[99]  L. Norton,et al.  The Norton-Simon hypothesis revisited. , 1986, Cancer treatment reports.